1ISG-039 The cost-savings potential of biosimilar drugs: a budget impact analysis

Piras, Maria Rita; Naddeo, C; Bettio, Marcelle; Draghi, Riccardo; Venturini, Francesca

doi:10.1136/ejhpharm-2019-eahpconf.39

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Simoens et al [ 16 ] published a review of budget impact analyses (BIA) of the use of biosimilars, although only focused mainly on two molecules, infliximab and etanercept. Furthermore, several recent studies have tried to estimate the budget impact of the introduction of recent biosimilars for either one or several molecules, at national or local levels in Italy [ 17 , 18 , 19 ], the UK [ 20 , 21 ] and Canada [ 22 ], including also in Canada a simulation exercise in which different penetration scenarios similar to the OECD average were considered [ 23 ]. In Spain, to date, the work by González Domínguez et al [ 24 ] is the only previous study that estimated the savings due to biosimilars.…”

Section: Introductionmentioning

confidence: 99%

Budget Impact Analysis of Biosimilar Products in Spain in the Period 2009–2019

García-Goñi

Río-Álvarez²,

Carcedo³

et al. 2021

Pharmaceuticals

View full text Add to dashboard Cite

Since the first biosimilar medicine, Omnitrope® (active substance somatropin) was approved in 2006, 53 biosimilars have been authorized in Spain. We estimate the budget impact of biosimilars in Spain from the perspective of the National Health System (NHS) over the period between 2009 and 2019. Drug acquisition costs considering commercial discounts at public procurement procedures (hospital tenders) and uptake data for both originator and biosimilar as actual units consumed by the NHS were the two variables considered. Two scenarios were compared: a scenario where no biosimilars are available and the biosimilar scenario where biosimilars are effectively marketed. All molecules exposed to biosimilar competition during this period were included in the analysis. The robustness of the model was tested by conducting multiple sensitivity analyses. From the payer perspective, it is estimated that the savings produced by the adoption of biosimilars would reach EUR 2306 million over 11 years corresponding to the cumulative savings from all biosimilars. Three molecules (infliximab, somatropin and epoetin) account for 60% of the savings. This study provides the first estimation of the financial impact of biosimilars in Spain, considering both the effect of discounts that manufacturers give to hospitals and the growing market share of biosimilars. We estimate that in our last year of data, 2019, the savings derived from the use of biosimilars relative total pharmaceutical spending in Spain is 3.92%. Although more research is needed, our evidence supports the case that biosimilars represent a great opportunity to the sustainability of the NHS through rationalizing pharmaceutical spending and that the full potential of biosimilar-savings has not been achieved yet, as there is a high variability in biosimilar uptake across autonomous regions.

show abstract